header
Local cover image
Local cover image
Image from OpenLibrary

Evaluation of the efficacy of human antibodies against hepatitis C virus antigens / Eman Ahmed Salem Ahmed Reda ; Supervised Sanaa Osman , Amr Saad , Ashraf Abdou Tabll

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Eman Ahmed Salem Ahmed Reda , 2016Description: 125 P. : charts , facsimiles ; 25cmOther title:
  • تقييم فعالية الأجسام المضادة البشرية ضد أنتجينات فيروس الكبد الوبائى سى [Added title page title]
Subject(s): Online resources: Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Biochemistry Summary: Hepatitis C virus (HCV) is a major health problem worldwide particularly in Egypt. The humoral immune response has an important function in the control of HCV infection. To study the role of neutralizing antibodies in Hepatitis C Virus (HCV) clearance in infected individuals. This study was carried out on apparently healthy blood donors (n=200). Detectable HCV antibodies were assessed by commercial ELISA. Specific human immunoglobulin targeting peptides derived from HCV E1 /E2 regions in blood samples were measured by in house optimized ELISA. Human IgG purification was carried out from both samples positive and negative for HCV RNA in order to evaluate its neutralizing activity invitro using Huh 7 cells. The studied cohort included 96/200 subjects who were positive for HCV antibodies, among which: 56/96 (58%) samples were positive for HCV RNA (group 1) and 40/96 (42%) samples had undetectable HCV RNA (group 2). ELISA results showed that Human HCV Immunoglobulin (HHI) targeting HCV E1 synthetic peptide (a.a 315- 323) was detectable in 63/96 (66%) and HHI targeting HCV E2 (a.a 412- 419) were positive in 14/96 (15%) while19/96 (19%) were positive for HCV E2 (a.a 517-531). (HHI) higher than the cutoff level against peptide HCV E1 (a.a 315-323) were detected in 22/63 (35%) in blood donors group 2 and positive in 41/63 (65%) in group 1. HHI against peptide HCV E2 (a.a 412-419) were positive in 7 (50%) in blood donors group 2 and also positive in 7 (50%) of group 1. In addition HHI targeting HCV E2 (a.a517-531) were positive in 11 (60%) in group 2 compared with 8 cases (40%) in group 1. Purified human antibodies from cases positive for HCV antibodies and negative for HCV RNA showed invitro neutralization at concentrations 30 and 10 æg/ml while the same concentration of purified human IgG from cases positive for HCV RNA showed no viral neutralization. The tested epitope (s) derived from HCV envelope E1 and E2, are important for viral clearance and hence can be used for HCV vaccine development
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.12.02.M.Sc.2016.Em.E (Browse shelf(Opens below)) Not for loan 01010110071474000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.12.02.M.Sc.2016.Em.E (Browse shelf(Opens below)) 71474.CD Not for loan 01020110071474000

Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Biochemistry

Hepatitis C virus (HCV) is a major health problem worldwide particularly in Egypt. The humoral immune response has an important function in the control of HCV infection. To study the role of neutralizing antibodies in Hepatitis C Virus (HCV) clearance in infected individuals. This study was carried out on apparently healthy blood donors (n=200). Detectable HCV antibodies were assessed by commercial ELISA. Specific human immunoglobulin targeting peptides derived from HCV E1 /E2 regions in blood samples were measured by in house optimized ELISA. Human IgG purification was carried out from both samples positive and negative for HCV RNA in order to evaluate its neutralizing activity invitro using Huh 7 cells. The studied cohort included 96/200 subjects who were positive for HCV antibodies, among which: 56/96 (58%) samples were positive for HCV RNA (group 1) and 40/96 (42%) samples had undetectable HCV RNA (group 2). ELISA results showed that Human HCV Immunoglobulin (HHI) targeting HCV E1 synthetic peptide (a.a 315- 323) was detectable in 63/96 (66%) and HHI targeting HCV E2 (a.a 412- 419) were positive in 14/96 (15%) while19/96 (19%) were positive for HCV E2 (a.a 517-531). (HHI) higher than the cutoff level against peptide HCV E1 (a.a 315-323) were detected in 22/63 (35%) in blood donors group 2 and positive in 41/63 (65%) in group 1. HHI against peptide HCV E2 (a.a 412-419) were positive in 7 (50%) in blood donors group 2 and also positive in 7 (50%) of group 1. In addition HHI targeting HCV E2 (a.a517-531) were positive in 11 (60%) in group 2 compared with 8 cases (40%) in group 1. Purified human antibodies from cases positive for HCV antibodies and negative for HCV RNA showed invitro neutralization at concentrations 30 and 10 æg/ml while the same concentration of purified human IgG from cases positive for HCV RNA showed no viral neutralization. The tested epitope (s) derived from HCV envelope E1 and E2, are important for viral clearance and hence can be used for HCV vaccine development

Issued also as CD

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image